← Back to Home

Anti-IL-17 Therapy Added for Polymyalgia Rheumatica: FDA Approves Cosentyx to Help Reduce Patients’ Steroid Burden

For patients who repeatedly relapse during tapering, controlling inflammation while reducing steroids is often difficult. Secukinumab increased sustained remission rates in a phase 3 trial, but fewer than half achieved the target within one year.

By SURL BioNews

For patients with polymyalgia rheumatica, treatment often presents another challenge after pain subsides: symptoms may return as soon as steroids are tapered. Novartis announced on November 17 that the U.S. Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) for adults who have an inadequate response to steroids or cannot tolerate steroid tapering, adding an option to a treatment course often marked by repeated setbacks.

Polymyalgia rheumatica (PMR) primarily affects adults over 50 and commonly causes pain and stiffness in the shoulders, neck, and hips. Steroids are important for controlling the disease, but long-term use increases risks such as osteoporosis and diabetes. The value of a new therapy therefore lies not only in suppressing inflammation, but also in whether it allows patients to maintain stable disease with less steroid use.

Secukinumab is a monoclonal antibody that blocks interleukin-17A (IL-17A), thereby inhibiting signals involved in inflammation. This approval makes it the first anti-IL-17 biologic approved to treat PMR in the United States. This “first” refers to its mechanism of action and does not mean that other biologic options were previously unavailable for PMR.

The approval was based on the phase 3 REPLENISH trial. The study enrolled 381 adults who had experienced a relapse during steroid tapering and randomly assigned them to receive 150 mg or 300 mg of secukinumab or placebo. All three groups also followed a 24-week prednisone tapering regimen and were followed through week 52. This design tested whether adding the new drug could improve disease control during tapering.

The sustained remission rate was 40.5% in the approved 150 mg group, compared with 20.5% in the placebo group, a difference of approximately 20 percentage points. The assessment required patients to achieve remission at week 12 and, through week 52, require no additional rescue treatment for a PMR relapse or newly diagnosed giant cell arteritis. In other words, the result reflects the ability to maintain control over a period of time, rather than symptom improvement at a single follow-up visit.

The trial also showed a reduction in steroid use: the adjusted annual cumulative glucocorticoid dose was 1683.2 mg in the 150 mg group and 2093.0 mg in the placebo group. However, a lower dose alone does not directly establish that long-term complications such as fractures or diabetes were also reduced. The trial also did not directly compare secukinumab with other PMR biologics, so these findings cannot yet establish the relative merits of different therapies.

The updated U.S. prescribing information lists the PMR regimen as 150 mg by subcutaneous injection at weeks 0, 1, 2, 3, and 4, followed by dosing every four weeks, initially alongside a tapering course of glucocorticoids. The prescribing information also retains warnings concerning serious infections, hypersensitivity, and inflammatory bowel disease. The higher sustained remission rate represents meaningful progress for patients who struggle to taper their medication. However, fewer than half achieved the target within one year, and long-term disease control and medication risks remain challenges that treatment must address.

References

  1. Novartis
  2. Novartis Pharmaceuticals Corporation
  3. Pharmacy Times